50 microgram matrix m adjuvant
chief executive officer novavax
chief executive officer sk bioscience
coronavirusspikesprotein
country: unknown
novavax' recombinant nanoparticle technology
protein based vaccine candidate
saponin based matrix m adjuvant
stanley c erck president
two pivotal phase 3 trials